Portola Pharmaceuticals appoints David Stump to its Board of Directors

– USA, CA – Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of David C. Stump, M.D., to its board of directors. Dr. Stump most recently served as executive vice president, research and development, at Human Genome Sciences, Inc.

“Dr. Stump has over 25 years of experience, most notably at Genentech and Human Genome Sciences, bringing some of the most successful drugs for heart disease, stroke, B-cell lymphoma and other cancers through the clinic and regulatory process to the market,” said Bill Lis, chief executive officer of Portola. “His knowledge, network and track record are directly and immediately relevant and applicable as we enter the pivotal phases of our three near-term pipeline opportunities that could transform Portola to a fully integrated commercial biopharmaceutical company in 2016.”

Dr. Stump’s career in the biotechnology industry spans more than 20 years. Prior to joining Human Genome Sciences, he held roles of increasing responsibility at Genentech, Inc., most recently as vice president, clinical research. Earlier in his career, he was named a Genentech Fellow. Before joining Genentech, he was an associate professor of medicine and biochemistry at the University of Vermont. Dr. Stump earned an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa. He completed postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. He is board certified in internal medicine, hematology and medical oncology. He is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He is also a member of the board of directors of Sunesis Pharmaceuticals, Inc. and MacroGenics, Inc.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its potentially life-saving therapies. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola’s partnered program is focused on developing selective Syk inhibitors for inflammatory conditions.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>